这项研究描述了一系列肽官能化的壳聚糖基纳米胶囊和脂质体与两种细胞系的相互作用之间的比较,即,小鼠巨噬细胞RAW264.7和人内皮细胞EA。hy926.两种类型的纳米载体都装载有磁性纳米颗粒,并设计用于抗炎治疗。这些磁性纳米结构的选择是基于它们在尺寸方面的优势,形态学,化学成分,以及修改其表面的多种可能性。此外,主动靶向可以通过使用外部磁场来确保。探讨壳聚糖基纳米胶囊和脂质体对细胞细胞学的影响,细胞活力,使用MTT测定法,和细胞形态进行了研究。结果表明,游离纳米胶囊的低至中等的细胞毒性和壳聚糖包被的脂质体负载地塞米松诱导的显著细胞毒性,确认其从交付系统中释放。因此,用纳米胶囊治疗48小时后,RAW264.7细胞的活力在88.18%之间变化(OCNPM-1I,3.125µg/mL)和76.37%(OCNPM-1,25µg/mL)。在同样的条件下,EA.在最高剂量(25µg/mL)下,hy926细胞活力介于99.91%(OCNPM-3,3.125µg/mL)和75.15%(OCNPM-3,25µg/mL)之间,这两个细胞系的值是相当的。关于地塞米松脂质体应用后的细胞反应性,在内皮细胞系中,RAW264.7细胞的最低活力为41.25%(CLDM5CP-1,25µg/mL)和58.20%(CLDMM2CP-11.25µg/mL),证明了纳米载体的选择性作用。细胞形态测试,执行以支持和确认MTT测试获得的结果,揭示了两种类型的纳米载体的不同反应。不出所料,在地塞米松脂质体的情况下,观察到强烈的细胞毒性作用和对无药物纳米胶囊缺乏细胞毒性.因此,我们的研究证明了所研究的纳米载体的生物相容性特征,这突出了它们作为潜在的药理学应用药物递送系统的未来研究,包括抗炎治疗.
This study describes the comparison between the interaction of a series of peptide-functionalized chitosan-based
nanocapsules and liposomes with two cell lines, i.e., mouse macrophages RAW 264.7 and human endothelial cells EA.hy926. Both types of nanocarriers are loaded with magnetic nanoparticles and designed for anti-inflammatory therapy. The choice of these magnetic nanostructures is argued based on their advantages in terms of size, morphology, chemical composition, and the multiple possibilities of modifying their surface. Moreover, active targeting might be ensured by using an external magnetic field. To explore the impact of chitosan-based
nanocapsules and liposomes on cell cytophysiology, the cell viability, using the MTT assay, and cell morphology were investigated. The results revealed low to moderate cytotoxicity of free
nanocapsules and significant cytotoxicity induced by chitosan-coated liposomes loaded with dexamethasone, confirming its release from the delivery system. Thus, after 48 h of treatment with
nanocapsules, the viability of RAW 264.7 cells varied between 88.18% (OCNPM-1I, 3.125 µg/mL) and 76.37% (OCNPM-1, 25 µg/mL). In the same conditions, EA.hy926 cell viability was between 99.91% (OCNPM-3, 3.125 µg/mL) and 75.15% (OCNPM-3, 25 µg/mL) at the highest dose (25 µg/mL), the values being comparable for both cell lines. Referring to the cell reactivity after dexamethasone-loaded liposome application, the lowest viability of RAW 264.7 cells was 41.25% (CLDM5CP-1, 25 µg/mL) and 58.20% (CLDMM2CP-1 1.25 µg/mL) in the endothelial cell line, proving a selective character of action of nanocarriers. The cell morphology test, performed to support and confirm the results obtained by the MTT test, revealed a differentiated response for the two types of nano-carriers. As expected, an intense cytotoxic effect in the case of dexamethasone-loaded liposomes and a lack of cytotoxicity for drug-free
nanocapsules were noticed. Therefore, our study demonstrated the biocompatible feature of the studied nanocarriers, which highlights them for future research as potential drug delivery systems for pharmacological applications, including anti-inflammatory therapy.